Analysts revise GOSS forecasts amid regulatory uncertainty

What happened: On March 23, 2026, Cantor Fitzgerald downgraded Gossamer Bio (GOSS) to 'Neutral' from 'Overweight', citing the negative Phase 3 PROSERA readout and regulatory uncertainty. Despite this, bullish analysts still see major upside, with a consensus price target of $1.00 indicating an upside potential of 150%. Meanwhile, Modelo maker Constellation Brands withdrew its 2028 guidance due to uncertainty in the rapidly evolving macroenvironment.

Market impact: The downgrade of GOSS, a penny stock with high analyst coverage, has sparked uncertainty in the biotech sector. The withdrawal of Constellation Brands' guidance signals a shift in consumer behavior and macroeconomic uncertainty, affecting the broader consumer staples sector.

What to watch next: Investors should monitor Gossamer Bio's regulatory updates, particularly the FDA's response to the PROSERA setback. Additionally, Constellation Brands' Q4 earnings, scheduled for May 2026, will provide insights into the company's performance amidst the evolving macroenvironment.